瑞舒伐他汀对急性脑梗死患者颈动脉内膜中层厚度及炎性反应的影响

Effect of rosuvastatin on the carotid artery intima-media thickness and inflammatory response in patients with acute cerebral infarction

目的观察瑞舒伐他汀对急性脑梗死患者颈动脉内膜中层厚度及炎性反应的影响。方法将入选的94例急性脑梗死患者随机分为治疗组48例和对照组46例。对照组用常规治疗方法,不服用他汀类药物;治疗组在对照组常规治疗的基础上加瑞舒伐他汀钙10 mg/次,每日1次口服。两组均连续治疗6个月。观察两组治疗前后的疗效、颈动脉内膜中层厚度(IMT)及超敏C-反应蛋白(hs-CRP)含量的变化情况。结果用药6个月后,治疗组的神经功能缺损评分较治疗前和对照组显著降低(P均<0.01);治疗组的总有效率显著高于对照组(P<0.05)。治疗组IMT、血清hs-CRP含量比治疗前及对照组均显著降低(P<0.05或P<0.01)。瑞舒伐他汀的不良反应轻微。结论瑞舒伐他汀能有效降低颈动脉内膜中层厚度及hs-CRP含量,减轻血管炎性反应,稳定和减轻颈动脉粥样硬化斑块,疗效明显,安全性好。

Objective To observe the effect of rosuvastatin on the carotid artery intima-media thickness and inflammatory response in patients with acute cerebral infarction. Methods Ninty-four patients with acute cerebral infarction patients were divided into treatment group（48 patients） and control group（46 patients）.The control group received routine treatment,not taking statins,the treatment group increased oral rosuvastatin calcium（10 mg/time,once a day） on the basis of conventional treatment.Both groups received continuous medication for 6 months.Efficacy,carotid artery intima-media thickness（IMT） and high sensitivity C-reactive protein（hs-CRP） concentration were observed in the two groups before and after treatment.Results After 6 months treatment,the neurological deficit score of the treatment group was significantly lower than the control group and before treatment（all P0.01）,the total effective rate of the treatment group was significantly higher than that of the control group（P0.05）.The IMT,serum hs-CRP levels of the treatment group were significantly lower than that before treatment and the control groups（P0.05 or P0.01）,the adverse reactions of rosuvastatin were mild. Conclusion Rosuvastatin can reduce carotid intima-media thickness and hs-CRP levels,reduce blood vessel inflammation,stability and reduce carotid atherosclerotic plaques,and the effect is obvious,the security is good.